127 related articles for article (PubMed ID: 15648946)
1. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.
Borchmann P; Schnell R; Schulz H; Engert A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1262-7. PubMed ID: 15648946
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of Hodgkin's lymphoma.
Borchmann P; Schnell R; Engert A
Eur J Haematol Suppl; 2005 Jul; (66):159-65. PubMed ID: 16007886
[TBL] [Abstract][Full Text] [Related]
3. Current strategies of antibody-based treatment in Hodgkin's disease.
Schnell R; Borchmann P; Schulz H; Engert A
Ann Oncol; 2002; 13 Suppl 1():57-66. PubMed ID: 12078905
[TBL] [Abstract][Full Text] [Related]
4. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Schnell R; Dietlein M; Staak JO; Borchmann P; Schomaecker K; Fischer T; Eschner W; Hansen H; Morschhauser F; Schicha H; Diehl V; Raubitschek A; Engert A
J Clin Oncol; 2005 Jul; 23(21):4669-78. PubMed ID: 16034043
[TBL] [Abstract][Full Text] [Related]
6. Experimental therapy in Hodgkin's disease.
Engert A; Pohl C; Diehl V
Ann Oncol; 1992 Sep; 3 Suppl 4():97-100. PubMed ID: 1333274
[TBL] [Abstract][Full Text] [Related]
7. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
Vose JM
Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy in Hodgkin's lymphoma.
Mendler JH; Friedberg JW
Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
[TBL] [Abstract][Full Text] [Related]
9. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
[TBL] [Abstract][Full Text] [Related]
10. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
Dasanu CA
J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
[TBL] [Abstract][Full Text] [Related]
11. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M
Cancer Res; 1990 Nov; 50(21):6944-8. PubMed ID: 2170012
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of the Non-Hodgkin's Lymphomas.
Knox SJ
Semin Radiat Oncol; 1995 Oct; 5(4):331-341. PubMed ID: 10717155
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy and colorectal cancer.
Koppe MJ; Bleichrodt RP; Oyen WJ; Boerman OC
Br J Surg; 2005 Mar; 92(3):264-76. PubMed ID: 15739250
[TBL] [Abstract][Full Text] [Related]
14. Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells.
Hsu SM; Ho YS; Hsu PL
J Natl Cancer Inst; 1987 Nov; 79(5):1091-9. PubMed ID: 3479635
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
DeNardo GL
Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
[TBL] [Abstract][Full Text] [Related]
16. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
Martin P; Furman RR; Coleman M; Leonard JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5636s-5642s. PubMed ID: 17875800
[TBL] [Abstract][Full Text] [Related]
17. [Current treatment for malignant lymphomas].
Usui N
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2191-9. PubMed ID: 18079619
[TBL] [Abstract][Full Text] [Related]
18. SGN-30 (Seattle genetics).
Schnell R; Borchmann P
Curr Opin Mol Ther; 2006 Apr; 8(2):164-72. PubMed ID: 16610770
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
